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abstractBACKGROUND: Lithium is a benchmark treatment for bipolar disorder in adults. Deﬁnitive studies
of lithium in pediatric bipolar I disorder (BP-I) are lacking.
METHODS: This multicenter, randomized, double-blind, placebo-controlled study of pediatric
participants (ages 7–17 years) with BP-I/manic or mixed episodes compared lithium (n = 53)
versus placebo (n = 28) for up to 8 weeks. The a priori primary efﬁcacy measure was change
from baseline to the end of study (week 8/ET) in the Young Mania Rating Scale (YMRS) score,
based on last-observation-carried-forward analysis.
RESULTS: The change in YMRS score was signiﬁcantly larger in lithium-treated participants (5.51
[95% conﬁdence interval: 0.51 to 10.50]) after adjustment for baseline YMRS score, age group,
weight group, gender, and study site (P = .03). Overall Clinical Global
Impression–Improvement scores favored lithium (n = 25; 47% very much/much improved)
compared with placebo (n = 6; 21% very much/much improved) at week 8/ET (P = .03).
A statistically signiﬁcant increase in thyrotropin concentration was seen with lithium
(3.0 6 3.1 mIU/L) compared with placebo (–0.1 6 0.9 mIU/L; P , .001). There was no
statistically signiﬁcant between-group difference with respect to weight gain.
CONCLUSIONS: Lithium was superior to placebo in reducing manic symptoms in pediatric patients
treated for BP-I in this clinical trial. Lithium was generally well tolerated in this patient
population and was not associated with weight gain, distinguishing it from other agents
commonly used to treat youth with bipolar disorder.
WHAT’S KNOWN ON THIS SUBJECT: Strictly-
deﬁned pediatric bipolar I disorder (BP-I) is
a serious condition. Although lithium is
a benchmark treatment and has shown
effectiveness in adults for decades, no deﬁnitive
efﬁcacy or long-term safety studies had been
performed in pediatric patients with BP-I.
WHAT THIS STUDY ADDS: This study provides
evidence to support the efﬁcacy of lithium in the
acute treatment of youths with BP-I who are
currently in a manic or mixed state. Lithium had
an adverse effect proﬁle that was acceptable for
most patients.
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Bipolar I disorder (BP-I) is a highly
impairing mood disorder that often
has its onset before adulthood.1 It is
a psychiatric condition that occurs in
pediatric patients worldwide.2 This
chronic disorder is characterized by
periods of spontaneous, abnormally
elevated mood and abnormally
irritable mood.3 BP-I is associated
with substantial disability,4 suicide
attempts,5,6 reduced quality of
life, and signiﬁcant functional
impairment.7–9
Lithium has long been a benchmark
treatment of adults with BP-I.10–14
Despite lithium’s use for BP-I in
adults, deﬁnitive placebo-controlled,
methodologically stringent studies of
efﬁcacy have not been available for
children.15
The Best Pharmaceuticals for
Children Act was signed into law in
2002 and re-authorized in 2007
under the Food and Drug
Administration Amendments Act and
in 2012 under the Food and Drug
Administration Safety and Innovation
Act.16 The law incorporates as its key
legislative goals: (1) prioritizing the
study of off-patent drugs used in
children; and (2) sponsoring clinical
trials when a pharmaceutical
company declines to perform them. In
2005, a written request from the US
Food and Drug Administration was
sent to the National Institutes of
Health, who, in turn, developed
a contract with a consortium of
experts in the ﬁeld of child and
adolescent psychiatry to conduct
a rigorous and comprehensive set of
clinical studies of lithium in children
with BP-I. Hence, the Collaborative
Lithium Trials were conducted.
One of the foremost purposes of the
Collaborative Lithium Trials was to
examine the acute efﬁcacy and long-
term safety of lithium in participants
aged 7 to 17 years with BP-I. After
establishing the pharmacokinetics,
the empirically determined dosing
strategy, and tolerability through an
initial set of studies,17,18 the ﬁrst
randomized, double-blind, placebo-
controlled lithium acute efﬁcacy
trial was conducted in a different
patient sample. The present article
describes the key ﬁndings of
that trial and the impact the results
may have on pediatric mental
health.
METHODS
We conducted a multicenter,
randomized, placebo-controlled
outpatient trial to examine lithium
in the acute treatment of pediatric
patients with BP-I. Details of the
study design and methods are
presented elsewhere19 and are brieﬂy
summarized here. Outpatient
participants were enrolled at 1 of 10
academic medical centers in the
United States that are experienced in
pediatric psychiatric care. The study
duration for each participant in this
efﬁcacy clinical trial was up to 8
weeks, with visits completed at weeks
1, 2, 3, 4, 6, and 8 and telephone
assessments at day 3 of week 1, week
5, and week 7. The ﬁrst participant
was enrolled on June 2, 2010,
and date of study completion for
the last participant was February 7,
2013.
Study Participants
Children aged 7 to 17 years meeting
unmodiﬁed Diagnostic and Statistical
Manual of Mental Disorders, Fourth
Edition, criteria for BP-I currently in
a manic or mixed episode, scoring
$20 on the Young Mania Rating Scale
(YMRS),20 having a negative drug
screen at baseline and remaining
drug-free through the study period,
and willing and clinically able to
undergo a washout period for all
psychotropic medications were
eligible. Children were ineligible if
they: were clinically stable on
a medication regimen for BP-I;
diagnosed with schizophrenia or
schizoaffective disorder, a pervasive
developmental disorder, anorexia
nervosa, bulimia nervosa, obsessive-
compulsive disorder, substance
dependence, symptoms of mania that
were attributable to a general medical
condition or secondary to use of
medications or general medical
condition including neurologic
disease, diabetes mellitus, thyroid
dysfunction, or renal dysfunction
that might be adversely affected by
lithium; had clinically signiﬁcant
abnormal laboratory assessments
that could inﬂuence the efﬁcacy or
safety of lithium or would complicate
interpretation of study results; had
evidence of serious homicidal/
suicidal ideation or active
hallucinations and delusions such
that in the treating physician’s
opinion it would not be
appropriately safe for the subject
to participate in this study; or had
concomitant prescription of over-
the-counter medication or
nutritional supplements that would
interact with lithium or affect the
participant’s physical or mental
status.
Initially, the prescription of
concomitant psychostimulants was
precluded. However, starting in June
2011, to enhance recruitment and
retention, participants with
comorbid attention-deﬁcit/
hyperactivity disorder were able to
receive psychostimulants after 4
weeks of double-blind therapy at the
treating physician’s discretion.
Melatonin (up to 3 mg) at bedtime
was permitted to treat insomnia.
Institutional Review Board Review
and Informed Consent
Local institutional review board
approval of the protocol, informed
consent, advertising, and all
amendments were obtained at each of
the 10 study sites before
implementation. Before the initiation
of any study-related procedures, the
informed consent statement was
signed by the participant’s parent or
legal guardian and by the person who
was authorized to administer the
informed consent. Children who
could read and understand the assent
form were asked to give written
assent.
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Diagnostic Procedures
Eligible participants underwent
a psychiatric interview with a board-
certiﬁed or board-eligible child and
adolescent psychiatrist. This
interview was followed by an
assessment with an interviewer/rater
trained on study-speciﬁc procedures
using the Schedule for Affective
Disorders and Schizophrenia for
School-Age Children–Present and
Lifetime Version (K-SADS-PL)21 to
conﬁrm the clinician’s diagnosis.
Initial training presentations were
provided for the K-SADS-PL, the
YMRS, the Children’s Depression
Rating Scale–Revised (CDRS-R),22,23
and the Columbia Suicide Severity
Rating Scale24 for raters across all 10
sites. Raters were considered trained
if they scored within 20% of the
gold standard score for the YMRS
and CDRS-R videos (established by
the lead clinical site Principal
Investigator) in addition to
completing a written examination
regarding administration of the K-
SADS-PL. Inter-rater reliability was
completed on the CDRS-R and the
YMRS every 6 months to ensure
consistency between raters at all
sites.
Randomization, Masking, and Drug
Administration
Participants were enrolled into the
study and were randomized to
receive lithium or matching placebo
in a 2 (lithium):1 (placebo) allocation
ratio. Stratiﬁcation factors included
study site, age at randomization
(7–11 years and 12–17 years), and
gender (male and female). The
randomization list was created
by an unblinded BPCA data
coordinating center (DCC)
statistician. Unblinded site staff
members were provided
randomization assignments via an
electronic data capture system.
The dosing of lithium used in the
present study was based on previous
research conducted by this
investigative group.17,18 The starting
dose of lithium (supplied as 300-mg,
regular-release capsules) was either
600 or 900 mg/d. Participants weighing
,30 kg started with 600 mg/d; all
other participants began lithium
therapy with 900 mg/d. Dose
increases of 300 mg/d could occur
at study visits and via telephone call
during the middle of the ﬁrst week
of randomized treatment unless
the participant had the following:
had met dosing response criteria
(deﬁned as a Clinical Global
Impression–Improvement scale [CGI-
I]25 score #2 and a 50% decrease
in the YMRS score from baseline
assessment); experienced $1 adverse
effect that signiﬁcantly affected
functioning that was at least of
moderate severity; had a serum lithium
level .1.4 mEq/L; or if the dose
exceeded 40 mg/kg/d (with the
exception of participants weighing
,23 kg, who could receive up to
900 mg/d). Participants randomized
to receive placebo were preassigned to
a maximum dose at randomization to
maintain the integrity of the blind.
Adherence to study medication was
monitored by using a dosing diary and
pill counts.
Study Assessments
The a priori primary outcome
measure was the change from
baseline to the end of study (week 8/
early termination [ET]) on the YMRS
score, based on last-observation-
carried-forward (LOCF) values.
Beginning at baseline, psychometric
assessments performed at study
visits included the YMRS, the CDRS-R,
and the Clinical Global
Impression–Severity scale (CGI-S).24
Starting at week 1, the CGI-I was
obtained at study visits. The
Columbia Suicide Severity Rating
Scale was completed at each study
visit to assess for suicidal behavior
and ideation by a trained rater.
Baseline scores were compared with
subsequent scores during the 8-week
trial. Treatment safety at each visit
was evaluated based on the incidence
of adverse events (AEs), treatment-
emergent AEs, serious AEs,
treatment-emergent AEs leading to
study drug discontinuation, clinically
signiﬁcant laboratory ﬁndings, vital
signs, electrocardiogram
investigations, physical examination
abnormalities, and trough lithium
serum levels. Lithium levels were
obtained at all study visits.
AE Monitoring
Participants were monitored for the
presence of treatment-emergent AEs
by open-ended inquiry and use of the
Side Effects Form for Children and
Adolescents,26 the Neurological
Examination for Lithium,18 and the
Neurological Rating Scale27 at each
study visit. A 13-item expanded
version of the Neurological Rating
Scale was used to assess for potential
additional extrapyramidal adverse
effects. These additional items
include: (1) cogwheeling; (2) acute
dystonic reaction; and (3) subjective
sense of stiffness.
Items from the Side Effects Form
for Children and Adolescents, the
Neurological Examination for
Lithium, the Neurological Rating
Scale, or open-ended inquiry that
were reported as being present since
the last visit were documented at
each study visit. The study physician
who conducted the visit determined
whether the effects that were
reported constituted an AE and
whether the AE was related to study
medication.
The intensity or severity of AEs was
graded as follows: mild (awareness
of sign or symptom but easily
tolerated; not expected to have
a clinically signiﬁcant effect on the
participant’s overall health and well-
being; not likely to require medical
attention); moderate (discomfort
enough to cause interference with
usual activity or affects clinical
status; may require medical
intervention); or severe
(incapacitating or signiﬁcantly
affecting clinical status; likely
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requires medical intervention and/
or close follow-up).
Statistical Analyses and Sample Size
Determinations
Sample size determination was based
on interim conditional power analyses.
These analyses suggested that with
a total sample size of 100, there would
be 94% power to detect a statistically
signiﬁcant difference in the mean
change from baseline to week 8/ET in
YMRS scores in the 2 treatment arms,
based on LOCF values.
Efﬁcacy variables that were based on
assessment instruments
administered over the course of
weekly assessments in the study,
including the YMRS, the CDRS-R, and
the Children’s Global Assessment
Scale (CGAS),28 were analyzed
primarily on the basis of mean
change from baseline to end-of-study
scores according to LOCF methods.
These changes were assessed by
using an analysis of covariance
model, with change from baseline
score as the dependent variable,
baseline score as a covariate, and age
stratum, gender, weight (,30 kg and
$30 kg), study site (pooled), and
treatment group as factors.
The CGI-S and CGI-I (overall illness
scores) are measured on a Likert
scale and were analyzed by using
a logistic regression model. A
reduction of at least 2 points from
baseline to week 8/ET on the CGI-S
was considered an improvement for
this measure. A score of 1 or 2 on the
CGI-I measured at week 8/ET was
classiﬁed as an improvement on this
scale. Independent factors in the
logistic regression model were age
stratum, gender, weight (,30 kg or
$30 kg), and treatment group.
The categorical end points of
response and remission were
compared according to treatment
group. Response was deﬁned as
a reduction in baseline YMRS score
$50% and a CGI-I score of 1 or 2.
Remission was deﬁned as a YMRS
score #12 and a CGI-S score #2.
Cochran-Mantel-Haenszel tests were
performed to determine if there was
a signiﬁcant difference in proportions
between the treatment groups for
each of these end points.
All analyses were conducted by
using SAS version 9.2 or higher (SAS
Institute, Inc, Cary, NC).
RESULTS
Study Participants and
Characteristics
A total of 153 participants were
screened for possible inclusion into
this clinical trial. Of these 153, 81
(53%) were randomized to receive
lithium (n = 53) or placebo (n = 28)
based on a 2:1 allocation ratio. Fig 1
summarizes participants screened
and enrolled into the study.
Enrollment across the sites ranged
from 1 patient to 24 patients
randomized to study.
Table 1 displays the baseline
characteristics of the participants.
There were no statistically signiﬁcant
differences between the lithium and
placebo groups regarding the baseline
variables of age group, gender, race,
and ethnicity. Furthermore, there
were no statistically signiﬁcant
FIGURE 1
Participant ﬂow. aParticipant also experienced previous serious AE of aggression.
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differences between treatment groups
at baseline with regard to the most
recent episode (manic or mixed) and
YMRS, CDRS-R, CGAS, or CGI-S overall
illness scores.
There was no statistically signiﬁcant
difference between the treatment
groups with respect to length of study
participation. The mean 6 SD length of
study participation for lithium-treated
participants and placebo participants
was 47.5 6 16.6 days and 48.6 6 15.3
days, respectively. The mean lithium
serum level at study’s end was 0.98 6
0.47 mEq/L.
Details regarding end-of-study lithium
dosing are summarized in Table 2.The
mean daily dose for participants aged
7 to 11 years (n = 49) was 1292 6
420 mg and 1716 6 606 mg for
participants aged 12 to 17 years
(n = 32). With regard to weight, the
mean daily dose was 9566 225 mg for
participants weighing ,30 kg (n = 16)
and 1583 6 524 mg for participants
weighing $30 kg (n = 65).
The overall mean adherence rate
for medication dosing was 91.9 6
11.8%. The adherence rates for the
lithium and placebo groups were
TABLE 1 Baseline Demographic Characteristics, Symptoms, and Comorbid Diagnoses
Characteristic 7–11 Years of Age 12–17 Years of Age Total
Lithium (n = 32) Placebo (n = 17) Lithium (n = 21) Placebo (n = 11) Lithium (n = 53) Placebo (n = 28)
Age at baseline, y
Mean 6 SD 9.5 6 1.6 9.1 6 1.3 14.6 6 1.5 14.5 6 1.6 11.5 6 2.9 11.2 6 3.0
Median (Min–Max) 9.8 (7.3–11.9) 9.0 (7.0–11.6) 14.1 (12.3–17.3) 14.3 (12.5–16.7) 11.3 (7.3–17.3) 10.6 (7.0–16.7)
Gender, n (%)
Male 14 (43.8) 10 (58.8) 8 (38.1) 5 (45.5) 22 (41.5) 15 (53.6)
Female 18 (56.3) 7 (41.2) 13 (61.9) 6 (54.5) 31 (58.5) 13 (46.4)
Ethnicity, n (%)
Hispanic or Latino 6 (18.8) 1 (5.9) 3 (14.3) 2 (18.2) 9 (17.0) 3 (10.7)
Not Hispanic or Latino 26 (81.3) 16 (94.1) 17 (81.0) 8 (72.7) 43 (81.1) 24 (85.7)
Not reported 0 0 1 (4.8) 1 (9.1) 1 (1.9) 1 (3.6)
Race, n (%)
White 18 (56.3) 10 (58.8) 12 (57.1) 4 (36.4) 30 (56.6) 14 (50.0)
African American 10 (31.3) 6 (35.3) 5 (23.8) 5 (45.5) 15 (28.3) 11 (39.3)
Asian 0 0 2 (9.5%) 0 2 (3.8) 0
.1 race 3 (9.4) 1 (5.9) 1 (4.8) 1 (9.1) 4 (7.5) 2 (7.1)
Not reported 1 (3.1) 0 1 (4.8) 1 (9.1) 2 (3.8) 1 (3.6)
Most recent episode, n (%)
Manic 15 (46.9) 10 (58.8) 8 (38.1) 8 (72.7) 23 (43.4) 18 (64.3)
Mixed 17 (53.1) 7 (41.2) 13 (61.9) 3 (27.3) 30 (56.6) 10 (35.7)
YMRS total score
Mean 6 SD 28.9 6 4.6 31.4 6 6.3 30.5 6 6.9 27.9 6 4.9 29.5 6 5.6 30.0 6 6.0
CDRS-R total score
Mean 6 SD 34.2 6 8.8 40.5 6 11.3 38.2 6 11.7 34.6 6 7.3 35.8 6 10.1 38.2 6 10.2
CGI-S score (overall illness), n (%)
4, moderately ill 17 (53.1) 4 (23.5) 10 (47.6) 8 (72.7) 27 (50.9) 12 (42.9)
5, markedly ill 13 (40.6) 12 (70.6) 9 (42.9) 3 (27.3) 22 (41.5) 15 (53.6)
6, severely ill 2 (6.3) 1 (5.9) 2 (9.5) 0 4 (7.5) 1 (3.6)
CGAS score
Mean 6 SD 51.2 6 6.2 50.4 6 7.2 47.7 6 6.9 49.6 6 4.3 49.8 6 6.7 50.1 6 6.1
Columbia Suicide Severity Rating Scale–Lifetime Ratings, n (%)
Suicidal ideation
Thoughts of their death 16 (50.0) 8 (47.1) 12 (57.1) 6 (54.6) 28 (52.8) 14 (50.0)
Nonspeciﬁc suicidal thoughts 4 (12.5) 3 (17.7) 6 (28.6) 1 (9.1) 10 (18.9) 4 (14.3)
Active thoughts of methods but
no clear plan
1 (3.1) 1 (5.9) 2 (9.5) 0 3 (5.7) 1 (3.6)
Active ideation with plan 1 (3.1) 3 (17.7) 3 (14.3) 2 (18.2) 4 (7.6) 5 (17.9)
History of suicide attempts 0 1 (5.9) 1 (4.8) 1 (9.1) 1 (1.9) 2 (7.1)
History of interrupted attempts 0 1 (5.9) 2 (9.5) 0 2 (3.8) 1 (3.6)
History of aborted attempts 0 1 (5.9) 0 0 0 1 (3.6)
Comorbid diagnoses, n (%)
ADHD 22 (68.8) 11 (64.7) 12 (57.1) 7 (63.6) 34 (64.2) 18 (64.3)
Disruptive behavior 7 (21.9) 3 (17.7) 4 (19.1) 3 (27.3) 11 (20.8) 6 (21.4)
Enuresis 1 (3.1) 2 (11.8) 0 0 1 (1.9) 2 (7.1)
Anxiety disorder 8 (25.0) 5 (29.4) 6 (28.6) 0 14 (26.4) 5 (17.9)
Othera 0 2 (11.8) 1 (4.8) 0 1 (1.9) 2 (7.1)
ADHD, attention-deﬁcit/hyperactivity disorder; Min–Max, minimum–maximum.
a Other includes 1 each of marijuana abuse, motor tic disorder, and trichotillomania.
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92.0 6 11.8% and 91.6 6 12.1%,
respectively.
Mania Response
The mean YMRS LOCF score at week 8
for lithium was 17.8 6 11.0, and for
placebo it was 22.3 6 9.7. The mean
change from baseline to week 8 LOCF
is illustrated in Figure 3. The change in
YMRS score at week 8 (ie, the primary
efﬁcacy measure) was signiﬁcant in
favor of lithium (P = .03). After
adjusting for baseline YMRS score, age
group, weight group, gender, and
study site, the treatment effect size
was 5.51 (95% conﬁdence interval:
0.51 to 10.50).
The adjusted standardized effect size
(Cohen’s d) and corresponding 95%
conﬁdence interval, adjusting for
baseline factors in the primary
efﬁcacy analysis, was 0.53 (0.06 to
0.99).29 The unadjusted standardized
effect size was 0.37 (–0.10 to 0.83).
Secondary Measures
For the CDRS-R, the mean decrease in
scores (reﬂecting reduced depressive
symptoms) was 5.5 6 12.2 on lithium
and 6.8 6 8.5 on placebo (P = .49).
CGAS scores increased (indicative of
improved global functioning) for
patients receiving lithium (9.5 6
13.8) and for those receiving placebo
(8.5 6 12.1) (P = .63). Scores in 22
(42%) of the lithium group
participants decreased at least 2
points (from baseline to week 8/ET)
on the CGI-S for overall illness
severity, whereas 6 (21%)
participants receiving placebo
decreased by at least 2 points. There
was no statistically signiﬁcant
between-group difference (P = .11).
However, overall CGI-I scores favored
lithium (n = 25; 47% very much/
much improved) compared with
placebo (n = 6; 21% very much/much
improved) at week 8/ET (P = .03).
Response and Remission
The number of participants meeting
a priori response criteria (reduction
in baseline YMRS score $50% and
CGI-I score of 1 or 2) was 17 (32%)
for lithium and 6 (21%) for placebo.
The number of participants meeting
criteria for remission (YMRS score
#12 and CGI-S score #2) at the end
of study was 14 (26%) for lithium
and 4 (14%) for placebo. There was
no statistically signiﬁcant difference
between treatment groups for either
response or remission.
Adverse Events
No participants discontinued the
study due to lack of tolerability. The
mean number of AEs per participant
was 6.4 (7.7 in the lithium group and
4.0 in the placebo group).
Seven AEs met the deﬁnition of
a serious AE. These 7 events occurred
among 6 participants (5 events in 4
lithium participants and 2 events in 2
placebo participants). None of the
serious AEs were believed to be
related to study medication.
Two lithium-treated participants
discontinued the study due to
persistent psychosis. Two lithium
participants and 1 placebo participant
discontinued because of suicidality;
all 3 of these discontinuations were
considered unrelated to the study
medication. Three additional AEs led
to study discontinuation: 1 lithium
participant with agitation, 1 lithium
participant with mood instability, and
1 placebo participant with aggressive
behavior. All of these discontinuations
were unrelated to study medication.
Table 3 lists those AEs occurring at
a rate of$5% and twice as frequently
on lithium as placebo. Most AEs were
mild to moderate in severity.
TABLE 2 Dosing and Weight at Last Study Visit According to Randomized Study Group
Variable Lithium (n = 53) Placebo (n = 28) Total (N = 81)
Dose, mg/d
Mean 6 SD 1483 6 584 1414 6 454 1459 6 540
Median (Min–Max) 1500 (300–3600) 1350 (600–2700) 1500 (300–3600)
Dose, mg/kg/d
Mean 6 SD 30.5 6 8.7 29.2 6 10.1 30.0 6 9.2
Median (Min–Max) 30.0 (5.9–50.0) 27.6 (10.0– 47.1) 29.0 (5.9–50.0)
Weight, kg
Mean 6 SD 51.8 6 22.5 52.7 6 19.8 52.1 6 21.5
Median (Min–Max) 47.2 (19.5–115.7) 50.5 (25.8–105.7) 47.8 (19.5–115.7)
End dose is the last nonzero dose reported. Min–Max, minimum–maximum.
FIGURE 2
Change in YMRS summary score according to visit in the intention-to-treat population. Baseline was
deﬁned as the ﬁrst visit of the efﬁcacy phase. Visits at weeks 5 and 7 were changed from clinic-
based visits to telephone calls with a protocol amendment on July 15, 2011 (with no YMRS data
collected).
890 FINDLING et al
The most common AEs with lithium
were vomiting (n = 24 [45%]),
nausea (n = 23 [43%]), and
headache (n = 19 [36%]). With
placebo, headache (n = 9 [32%]),
upper abdominal pain (n = 9 [32%]),
and nausea and increased appetite
(both at n = 5 [18%]) were most
common. Fourteen of the 24 lithium-
treated participants who experienced
vomiting had their ﬁrst episode
during week 1. The dose was reduced
in 12 of the 24 participants after
a vomiting episode. The mean 6 SD
length of time from onset of vomiting to
resolution (or end of phase) for lithium-
treated participants was 7.3 6 11.4
days; the mean length of time for
resolution of nausea was 14.7 6 17.3
days.
A weight gain of 0.9 6 1.6 kg was
reported in the lithium-treated
participants and a weight gain of 1.26
1.7 kg was observed in participants
receiving placebo (Figure 3). There
was no statistically signiﬁcant
between-group difference with
respect to weight gain. A statistically
signiﬁcant increase in thyrotropin
concentration of 3.0 6 3.1 mIU/L was
observed in those participants who
received lithium, compared with
–0.1 6 0.9 mIU/L in participants
receiving placebo (P , .001).
No participants discontinued
treatment as a result of any clinically
signiﬁcant ﬁndings related to vital
signs, physical examination, or
electrocardiography.
DISCUSSION
The present study comprises the
largest prospective, randomized,
double-blind, placebo-controlled
study to-date of lithium in youth aged
7 to 17 years with BP-I mixed or
FIGURE 3
Change in weight z score during the efﬁcacy phase. Change score is the week value minus the
baseline value; baseline is deﬁned as the ﬁrst visit of the efﬁcacy phase.
TABLE 3 AEs Seen at a Rate of $5% (n $ 5) in the Total Population and Twice as Frequently With Lithium as Placebo According to Age Strata and
Treatment Group
System Organ Class/Preferred Term 7–11 Years of Age 12–17 Years of Age Total
Lithium (n = 32) Placebo (n = 17) Lithium (n = 21) Placebo (n = 11) Lithium (n = 53) Placebo (n = 28)
Eye disorders
Blurred vision 4 (12.5%) 0 1 (4.8%) 0 5 (9.4%) 0
Gastrointestinal disorders
Abdominal pain 4 (12.5%) 0 2 (9.5%) 1 (9.1%) 6 (11.3%) 1 (3.6%)
Diarrhea 10 (31.3%) 3 (17.6%) 5 (23.8%) 1 (9.1%) 15 (28.3%) 4 (14.3%)
Nausea 12 (37.5%) 3 (17.6%) 11 (52.4%) 2 (18.2%) 23 (43.4%) 5 (17.9%)
Vomiting 15 (46.9%) 3 (17.6%) 9 (42.9%) 0 24 (45.3%) 3 (10.7%)
General disorders and administration site
conditions
Fatigue 0 0 5 (23.8%) 1 (9.1%) 5 (9.4%) 1 (3.6%)
Thirst 12 (37.5%) 0 3 (14.3%) 3 (27.3%) 15 (28.3%) 3 (10.7%)
Laboratory tests
Blood thyroid-stimulating hormone increased 4 (12.5%) 0 5 (23.8%) 0 9 (17.0%) 0
Metabolism and nutrition disorders
Decreased appetite 5 (15.6%) 1 (5.9%) 0 0 5 (9.4%) 1 (3.6%)
Nervous system disorders
Dizziness 7 (21.9%) 0 5 (23.8%) 2 (18.2%) 12 (22.6%) 2 (7.1%)
Sedation 6 (18.8%) 0 0 0 6 (11.3%) 0
Tremor 9 (28.1%) 2 (11.8%) 8 (38.1%) 0 17 (32.1%) 2 (7.1%)
Renal and urinary disorders
Pollakiuria (abnormally frequent urination) 10 (31.3%) 0 4 (19.0%) 2 (18.2%) 14 (26.4%) 2 (7.1%)
Skin and subcutaneous tissue disorders 0
Rash 3 (9.4%) 0 3 (14.3%) 0 6 (11.3%) 0
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manic episodes. The data provide
evidence that lithium was effective
in reducing manic symptoms in
approximately one-half of these
participants.
Lithium was superior to placebo in
reducing manic symptoms in these
patients, albeit with a delay of
between-group separation. Whether
the primary and secondary efﬁcacy
analyses would differ if this study
was a longer clinical trial remains an
empirical question that warrants
further study. Ethical considerations
during the design of the study
precluded a longer clinical trial with
one of the arms being placebo. The
dropout rates during this clinical trial
accentuate the challenges of
performing a double-blind, placebo-
controlled study in this population.
In addition to participant age, the
study results are similar to those of
a meta-analysis of lithium-controlled
trials in adults.12 The calculated mean
standardized effect size was reported
to be 0.40 with a range of 0.11 to
0.55. The clinical trial reported herein
suggests that the efﬁcacy of lithium
in children is similar to that reported
in adults and highlights that rigorous
study of an older drug can improve
the armamentarium of drugs used in
the pediatric population. These study
results add to the ﬁndings of the
other large pediatric bipolar study,
the National Institute of Mental
Health–funded TEAM (Treatment of
Early Age Mania) study, which
compared treatment with lithium,
divalproex, and risperidone in
outpatients.30 However, in that study,
lithium and divalproex were each
found to be less effective than
risperidone.
Lithium was generally well tolerated
in the present study. The adverse
effect proﬁle was consistent with
what has been previously reported in
adults. Of note, lithium was not
associated with weight gain relative
to placebo. This observation
distinguishes lithium from the
antipsychotic agents,31–34 some of
which have been shown to be
effective in the acute treatment of
manic and/or mixed states in this
population but with a risk of
substantial weight gain and metabolic
derangements.
A potential limitation of the present
study is that LOCF was used in the
analyses. LOCF may bias an estimate
of the treatment and underestimate
variability of the estimated result.
Sensitivity analyses have been
performed by using mixed model
repeated measures, which do not
include imputed data for missing
values and use all available YMRS
scores at each visit. Results of both
methods of analyses indicate the
statistically signiﬁcant superiority of
lithium versus placebo. The mixed
model repeated measures analyses
showed signiﬁcance only at the
week 6 and week 8 time points.
The study does have some
limitations. It was relatively brief,
and BP-I is a chronic, recurrent
condition; therefore, deﬁnitive
conclusions about long-term efﬁcacy
cannot be made from these data.
Another shortcoming of this research
is that current scientiﬁc methods
preclude the absolute certainty of
the diagnosis of BP-I in this cohort.
In addition, the study enrolled
a relatively small sample. Therefore,
uncommon adverse effects during
acute treatment were likely not
observed. The relatively modest
sample size may also explain why
between-group differences were not
found on the secondary efﬁcacy
measures. In addition, sample size
considerations limit the ability to
perform analyses on subpopulations
and extrapolation to a more general
pediatric population.
CONCLUSIONS
Lithium exhibited efﬁcacy in the
acute treatment of pediatric BP-I.
With the dosing regimen used,
lithium was found to have
a generally acceptable adverse effect
proﬁle. Although use of the
sustained-release formulation of
lithium may obviate vomiting, this
question is empirical and has not yet
been tested.
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